The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trial

G. Goodwin, S. Aaronson, B. Dunlop, D. Feifel, D. Hellerstein, N. Hewitt, L. Marwood, S. Mistry, M. Somers, S. Stansfield, J. Tsai, S. Williams, A. Young, S. Zisook, E. Malievskaia

Neuroscience Applied • January 1, 2022 Peer reviewed • DOI: 10.1016/j.nsa.2022.100511 • via Semantic Scholar